• 1
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012; 62(1): 1029.
  • 2
    Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J. Clin. Oncol. 2010; 28(7): 11171123.
  • 3
    Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL. Long-term multi-institutional analysis of stage T1–T2 prostate cancer treated with radiotherapy in the PSA era. Int. J. Radiat. Oncol. Biol. Phys. 2003; 57(4): 915928.
  • 4
    Vo T, Rifkin MD, Peters TL. Should ultrasound criteria of the prostate be redefined to better evaluate when and where to biopsy. Ultrasound Q. 2001; 17(3): 171176.
  • 5
    Rabbani F, Stroumbakis N, Kava BR, Cookson MS, Fair WR. Incidence and clinical significance of false-negative sextant prostate biopsies. J. Urol. 1998; 159(4): 12471250.
  • 6
    Cox JD, Kline RW. Do prostatic biopsies 12 months or more after external irradiation for adenocarcinoma, Stage III, predict long-term survival? Int. J. Radiat. Oncol. Biol. Phys. 1983; 9(3): 299303.
  • 7
    Kuban DA, el-Mahdi AM, Schellhammer P. The significance of post-irradiation prostate biopsy with long-term follow-up. Int. J. Radiat. Oncol. Biol. Phys. 1992; 24(3): 409414.
  • 8
    Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int. J. Radiat. Oncol. Biol. Phys. 2000; 48(2): 355367.
  • 9
    Hanlon AL, Diratzouian H, Hanks GE. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2002; 53(2): 297303.
  • 10
    Kestin LL, Vicini FA, Ziaja EL, Stromberg JS, Frazier RC, Martinez AA. Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy. Cancer 1999; 86(8): 15571566.
  • 11
    Pickett B, Kurhanewicz J, Coakley F, Shinohara K, Fein B, Roach M III. Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2004; 60(4): 10471055.
  • 12
    Pucar D, Shukla-Dave A, Hricak H, Moskowitz CS, Kuroiwa K, Olgac S, Ebora LE, Scardino PT, Koutcher JA, Zakian KL. Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy – initial experience. Radiology 2005; 236(2): 545553.
  • 13
    Sala E, Eberhardt SC, Akin O, Moskowitz CS, Onyebuchi CN, Kuroiwa K, Ishill N, Zelefsky MJ, Eastham JA, Hricak H. Endorectal MR imaging before salvage prostatectomy: tumor localization and staging. Radiology 2006; 238(1): 176183.
  • 14
    Westphalen AC, Kurhanewicz J, Cunha RM, Hsu IC, Kornak J, Zhao S, Coakley FV. T2-weighted endorectal magnetic resonance imaging of prostate cancer after external beam radiation therapy. Int. Braz J Urol 2009; 35(2): 171180; discussion 181–172.
  • 15
    Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ. Three-dimensional 1H MR spectroscopic imaging of the in situ human prostate with high (0.24–0.7 cm3) spatial resolution. Radiology 1996; 198(3): 795805.
  • 16
    Kurhanewicz J, Vigneron DB, Males RG, Swanson MG, Yu KK, Hricak H. The prostate: MR imaging and spectroscopy. Present and future. Radiol. Clin. North Am. 2000; 38(1): 115138, viii–ix.
  • 17
    Pickett B, Ten Haken RK, Kurhanewicz J, Qayyum A, Shinohara K, Fein B, Roach M III. Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging. Int. J. Radiat. Oncol. Biol. Phys. 2004; 59(3): 665673.
  • 18
    Roach M III, Kurhanewicz J, Carroll P. Spectroscopy in prostate cancer: hope or hype? Oncology (Williston Park) 2001; 15(11): 13991410; discussion 1415–1416, 1418.
  • 19
    Westphalen AC, Coakley FV, Roach M III, McCulloch CE, Kurhanewicz J. Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection. Radiology 2010; 256(2): 485492.
  • 20
    Kim CK, Park BK, Lee HM. Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI. J. Magn. Reson. Imaging 2009; 29(2): 391397.
  • 21
    Westphalen AC, Reed GD, Vinh PP, Sotto C, Vigneron DB, Kurhanewicz J. Multiparametric 3 T endorectal mri after external beam radiation therapy for prostate cancer. J. Magn. Reson. Imaging 2012; 36(2): 430437.
  • 22
    Haider MA, Chung P, Sweet J, Toi A, Jhaveri K, Menard C, Warde P, Trachtenberg J, Lockwood G, Milosevic M. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2008; 70(2): 425430.
  • 23
    Bong GW, Keane TE. Salvage options for biochemical recurrence after primary therapy for prostate cancer. Can. J. Urol. 2007; 14 Suppl. 1: 29.
  • 24
    Hsu CC, Hsu H, Pickett B, Crehange G, Hsu IC, Dea R, Weinberg V, Gottschalk AR, Kurhanewicz J, Shinohara K, Roach M III. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2013; 85(2): 270277.
  • 25
    Jabbari S, Hsu IC, Kawakami J, Weinberg VK, Speight JL, Gottschalk AR, Roach M III, Shinohara K. High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: technique and experience. Brachytherapy 2009; 8(4): 339344.
  • 26
    Lee B, Shinohara K, Weinberg V, Gottschalk AR, Pouliot J, Roach M III, Hsu IC. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int. J. Radiat. Oncol. Biol. Phys. 2007; 67(4): 11061112.
  • 27
    Moman MR, van den Berg CA, Boeken Kruger AE, Battermann JJ, Moerland MA, van der Heide UA, van Vulpen M. Focal salvage guided by T2-weighted and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer recurrences. Int. J. Radiat. Oncol. Biol. Phys. 2010; 76(3): 741746.
  • 28
    Mostofi FK, Sesterhenn IA, Davis CJ, Jr. A pathologist's view of prostatic carcinoma. Cancer 1993; 71(3 Suppl.): 906932.
  • 29
    Pickett B, Kurhanewicz J, Pouliot J, Weinberg V, Shinohara K, Coakley F, Roach M III. Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level. Int. J. Radiat. Oncol. Biol. Phys. 2006; 65(1): 6572.
  • 30
    Foltz WD, Wu A, Chung P, Catton C, Bayley A, Milosevic M, Bristow R, Warde P, Simeonov A, Jaffray DA, Haider MA, Menard C. Changes in apparent diffusion coefficient and T2 relaxation during radiotherapy for prostate cancer. J. Magn. Reson. Imaging 2013; 37(4): 909916.
  • 31
    Feneley MR, Young MP, Chinyama C, Kirby RS, Parkinson MC. Ki-67 expression in early prostate cancer and associated pathological lesions. J. Clin. Pathol. 1996; 49(9): 741748.
  • 32
    Pollack A, DeSilvio M, Khor L, Li R, Al-Saleem T, Hammond M, Venkatesan V, Byhardt R, Hanks GE, Roach M, Shipley WU, Sandler HM. Ki-67 staining is a strong predictor of patient outcome for prostate cancer patients treated with androgen deprivation plus radiotherapy: an analysis of RTOG 92-02. Int. J. Radiat. Oncol. Biol. Phys. 2003; 57(2 Suppl.): S200S201.
  • 33
    Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, Roach M III, Shipley WU, Hanks GE, Sandler HM. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J. Clin. Oncol. 2004; 22(11): 21332140.
  • 34
    Parker AS, Heckman MG, Wu KJ, Crook JE, Hilton TW, Pisansky TM, Bernard JR, Schild SE, Khor LY, Hammond EH, Pollack A, Buskirk SJ. Evaluation of Ki-67 staining levels as an independent biomarker of biochemical recurrence after salvage radiation therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2009; 75(5): 13641370.
  • 35
    Khor LY, Bae K, Paulus R, Al-Saleem T, Hammond ME, Grignon DJ, Che M, Venkatesan V, Byhardt RW, Rotman M, Hanks GE, Sandler HM, Pollack A. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02. J. Clin. Oncol. 2009; 27(19): 31773184.
  • 36
    Keshari KR, Tsachres H, Iman R, Delos Santos L, Tabatabai ZL, Shinohara K, Vigneron DB, Kurhanewicz J. Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage – impact of tissue environment. NMR Biomed. 2011; 24(6): 691699.
  • 37
    Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res. 2001; 61(9): 35993603.
  • 38
    Glunde K, Ackerstaff E, Mori N, Jacobs MA, Bhujwalla ZM. Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol. Pharm. 2006; 3(5): 496506.
  • 39
    Levin YS, Albers MJ, Butler TN, Spielman D, Peehl DM, Kurhanewicz J. Methods for metabolic evaluation of prostate cancer cells using proton and 13C HR-MAS spectroscopy and [3-13C] pyruvate as a metabolic substrate. Magn. Reson. Med. 2009; 62(5): 10911098.
  • 40
    Swanson MG, Keshari KR, Tabatabai ZL, Simko JP, Shinohara K, Carroll PR, Zektzer AS, Kurhanewicz J. Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy. Magn. Reson. Med. 2008; 60(1): 3340.
  • 41
    Swanson MG, Vigneron DB, Tabatabai ZL, Males RG, Schmitt L, Carroll PR, James JK, Hurd RE, Kurhanewicz J. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn. Reson. Med. 2003; 50(5): 944954.
  • 42
    Swanson MG, Zektzer AS, Tabatabai ZL, Simko J, Jarso S, Keshari KR, Schmitt L, Carroll PR, Shinohara K, Vigneron DB, Kurhanewicz J. Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn. Reson. Med. 2006; 55(6): 12571264.
  • 43
    Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J. Magn. Reson. Imaging 2002; 16(4): 451463.
  • 44
    Casciani E, Polettini E, Bertini L, Emiliozzi P, Amini M, Pansadoro V, Gualdi GF. Prostate cancer: evaluation with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiol. Med. 2004; 108(5-6): 530541.
  • 45
    Kumar R, Kumar M, Jagannathan NR, Gupta NP, Hemal AK. Proton magnetic resonance spectroscopy with a body coil in the diagnosis of carcinoma prostate. Urol. Res. 2004; 32(1): 3640.
  • 46
    Zakian KL, Sircar K, Hricak H, Chen HN, Shukla-Dave A, Eberhardt S, Muruganandham M, Ebora L, Kattan MW, Reuter VE, Scardino PT, Koutcher JA. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005; 234(3): 804814.
  • 47
    Albers MJ, Bok R, Chen AP, Cunningham CH, Zierhut ML, Zhang VY, Kohler SJ, Tropp J, Hurd RE, Yen YF, Nelson SJ, Vigneron DB, Kurhanewicz J. Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res. 2008; 68(20): 86078615.
  • 48
    Tessem MB, Swanson MG, Keshari KR, Albers MJ, Joun D, Tabatabai ZL, Simko JP, Shinohara K, Nelson SJ, Vigneron DB, Gribbestad IS, Kurhanewicz J. Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magn. Reson. Med. 2008; 60(3): 510516.
  • 49
    Verma S, Rajesh A, Futterer JJ, Turkbey B, Scheenen TW, Pang Y, Choyke PL, Kurhanewicz J. Prostate MRI and 3D MR spectroscopy: how we do it. Am. J. Roentgenol. 2010; 194(6): 14141426.
  • 50
    Albers MJ, Butler TN, Rahwa I, Bao N, Keshari KR, Swanson MG, Kurhanewicz J. Evaluation of the ERETIC method as an improved quantitative reference for 1H HR-MAS spectroscopy of prostate tissue. Magn. Reson. Med. 2009; 61(3): 525532.
  • 51
    Naressi A, Couturier C, Devos JM, Janssen M, Mangeat C, de Beer R, Graveron-Demilly D. Java-based graphical user interface for the MRUI quantitation package. MAGMA 2001; 12(2/3): 141152.
  • 52
    Ratiney H, Albers MJ, Rabeson H, Kurhanewicz J. Semi-parametric time-domain quantification of HR-MAS data from prostate tissue. NMR Biomed. 2010; 23(10): 11461157.
  • 53
    Swanson MG, Noworolski SM, Kurhanewicz J. Magnetic resonance spectroscopy and spectroscopic imaging of the prostate, breast, and liver. In: Webb GA (ed.), Modern Magnetic Resonance. Volume 1, pp. 113. Springer: P.O. Box 17, 3300 AA Dordrecht, The Netherlands. 2006.
  • 54
    Diggle P, Liang K-Y, Zeger SL. Analysis of Longitudinal Data. Oxford University Press: Oxford, 1994.
  • 55
    Costello LC, Franklin RB. Concepts of citrate production and secretion by prostate: 2. Hormonal relationships in normal and neoplastic prostate. Prostate 1991; 19(3): 181205.
  • 56
    Heerschap A, Jager GJ, van der Graaf M, Barentsz JO, Ruijs SH. Proton MR spectroscopy of the normal human prostate with an endorectal coil and a double spin-echo pulse sequence. Magn. Reson. Med. 1997; 37(2): 204213.
  • 57
    Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Percent Gleason grade 4/5 as prognostic factor in prostate cancer diagnosed at transurethral resection. J. Urol. 2002; 168(2): 509513.
  • 58
    Wills ML, Sauvageot J, Partin AW, Gurganus R, Epstein JI. Ability of sextant biopsies to predict radical prostatectomy stage. Urology 1998; 51(5): 759764.
  • 59
    Bhujwalla ZM, Aboagye EO, Gillies RJ, Chacko VP, Mendola CE, Backer JM. Nm23-transfected MDA-MB-435 human breast carcinoma cells form tumors with altered phospholipid metabolism and pH: a 31P nuclear magnetic resonance study in vivo and in vitro. Magn. Reson. Med. 1999; 41(5): 897903.
  • 60
    Usenius JP, Vainio P, Hernesniemi J, Kauppinen RA. Choline-containing compounds in human astrocytomas studied by 1H NMR spectroscopy in vivo and in vitro. J. Neurochem. 1994; 63(4): 15381543.
  • 61
    Podo F. Tumour phospholipid metabolism. NMR Biomed. 1999; 12(7): 413439.
  • 62
    Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res. 1999; 59(1): 8084.
  • 63
    Podo F, Canevari S, Canese R, Pisanu ME, Ricci A, Iorio E. MR evaluation of response to targeted treatment in cancer cells. NMR Biomed. 2011; 24(6): 648672.
  • 64
    Cuadrado A, Carnero A, Dolfi F, Jimenez B, Lacal JC. Phosphorylcholine: a novel second messenger essential for mitogenic activity of growth factors. Oncogene 1993; 8(11): 29592968.
  • 65
    Negendank W. Studies of human tumors by MRS – a review. NMD Biomed. 1992; 5(5): 303324.
  • 66
    Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, Carlson TP, Klein EA. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2004; 58(1): 2533.
  • 67
    Zietman AL, Chung CS, Coen JJ, Shipley WU. 10-year outcome for men with localized prostate cancer treated with external radiation therapy: results of a cohort study. J. Urol. 2004; 171(1): 210214.
  • 68
    Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhirst MW, Mueller-Klieser W. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2001; 51(2): 349353.
  • 69
    Schwickert G, Walenta S, Sundfor K, Rofstad EK, Mueller-Klieser W. Correlation of high lactate levels in human cervical cancer with incidence of metastasis. Cancer Res. 1995; 55(21): 47574759.
  • 70
    Walenta S, Chau TV, Schroeder T, Lehr HA, Kunz-Schughart LA, Fuerst A, Mueller-Klieser W. Metabolic classification of human rectal adenocarcinomas: a novel guideline for clinical oncologists? J. Cancer Res. Clin. Oncol. 2003; 129(6): 321326.
  • 71
    Walenta S, Schroeder T, Mueller-Klieser W. Lactate in solid malignant tumors: potential basis of a metabolic classification in clinical oncology. Curr. Med. Chem. 2004; 11(16): 21952204.
  • 72
    Cunningham CH, Vigneron DB, Chen AP, Xu D, Hurd RE, Sailasuta N, Pauly JM. Design of symmetric-sweep spectral-spatial RF pulses for spectral editing. Magn. Reson. Med. 2004; 52(1): 147153.
  • 73
    Chen AP, Bok B, Zhang VY, Xu D, Veeraraghavan S, Hurd RE, Nelson SJ, Kurhanewicz J, Vigneron DB. Serial hyperpolarized 13C 3D-MRSI following therapy in a mouse model of prostate cancer. Proceedings of the 16th Annual Meeting of ISMRM, Toronto, Ontario 3–9 May, 2008, program 888.
  • 74
    Day SE, Kettunen MI, Cherukuri MK, Mitchell JB, Lizak MJ, Morris HD, Matsumoto S, Koretsky AP, Brindle KM. Detecting response of rat C6 glioma tumors to radiotherapy using hyperpolarized [1- 13C]pyruvate and 13C magnetic resonance spectroscopic imaging. Magn. Reson. Med. 2011; 65(2): 557563.
  • 75
    Zhang VY, Bok R, Sukumar S, Cunha A, Hsu IC, Pouliot J, Vigneron D, Kurhanewicz J. Detecting early tumor response of prostate cancer to radiation therapy using multi-parametric 14T 1H and hyperpolarized 13C MR imaging. Proceedings of the 20th Annual Meeting of ISMRM, Melbourne, Australia 5–11 May, 2012, program 4319.
  • 76
    Garcia-Martin ML, Adrados M, Ortega MP, Fernandez Gonzalez I, Lopez-Larrubia P, Viano J, Garcia-Segura JM. Quantitative 1H MR spectroscopic imaging of the prostate gland using LCModel and a dedicated basis-set: correlation with histologic findings. Magn. Reson. Med. 2011; 65(2): 329339.
  • 77
    Cheng LL, Burns MA, Taylor JL, He W, Halpern EF, McDougal WS, Wu CL. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res. 2005; 65(8): 30303034.
  • 78
    Burns MA, He W, Wu CL, Cheng LL. Quantitative pathology in tissue MR spectroscopy based human prostate metabolomics. Technol. Cancer Res. Treat. 2004; 3(6): 591598.
  • 79
    Hambrock T, Somford DM, Hoeks C, Bouwense SA, Huisman H, Yakar D, van Oort IM, Witjes JA, Futterer JJ, Barentsz JO. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J. Urol. 2010; 183(2): 520527.